GLP-1s Are a $70B Market. Patients Still Turn to TikTok

GLP-1 medications like Ozempic, Wegovy, and Zepbound have become a $70 billion market, yet many patients are getting their day-to-day guidance from TikTok influencers rather than clinicians, according to MedCity News. The reason is structural: the healthcare system does a good job writing the prescription and a poor job supporting what comes next.

In practice, patients are left to figure out dosing schedules, manage nausea and other side effects, navigate nutrition and muscle loss, and decide what to do when symptoms hit. With little clinical follow-up, social media fills the void, and the advice ranges from helpful to dangerous. That gap carries real risk, including poor adherence, avoidable side effects, and patients abandoning therapy.

The opportunity is equally clear. Digital health companies, pharmacies, and providers that build structured, ongoing support around GLP-1 prescriptions can improve outcomes and capture loyalty in a fast-growing category. As MedCity News notes, closing the space between prescription and understanding is where the next phase of competition will play out.